

Staphylococcus epidermis and acne scar inflammations in young people

Asist Prof.Fakhri S.Alajeeli¹, Ali S.kadhum²

¹Al- Hadi University College -Department of Medical laboratory -Baghdad -Iraq.

²Wasit university – kut - Iraq.

*Corresponding Author: Asist Prof.Fakhri S.Alajeeli

DOI: <https://doi.org/10.55145/ajbms.2023.1.2.002>

Received April 2023; Accepted June 2023; Available June 2023

ABSTRACT: Staphylococcus epidermidis is a resilient microbe distinguished by its immobile, Gram-positive spherical cells that aggregate in clusters resembling grape clusters. Biochemical examinations reveal a faintly positive outcome in the nitrate reductase test for this microbe. It generates urease while lacking oxidase production. S. epidermidis possesses a transferrin-binding protein that facilitates the acquisition of iron from transferrin. The formation of biofilms on plastic devices plays a pivotal role in the pathogenicity of S. epidermidis and its connection to acne. This adaptable bacterium is frequently encountered as a nosocomial and commensal pathogen, recognized for its opportunistic behavior and its global impact on infections, primarily contracted within healthcare facilities. It displays a remarkable ability to establish strong biofilms on various surfaces, contributing to infections linked to catheters and heart valve implants. The transmission of the bacterium is easily facilitated through the contamination of the skin of hospital visitors and healthcare personnel.

Keywords: Acne scar, skin inflammation, Staphylococcus epidermidis, biofilm



1. INTRODUCTION

Us Staphylococcus epidermidis has long been recognized as the predominant bacterial colonizer of human skin [1]. A study of the healthy human microbiome has reinforced this, with S. epidermidis found to be universally present on the skin of study participants [2]. Due to this ubiquitous presence and fewer virulence factors compared to its more pathogenic relative, Staphylococcus aureus, historically S. epidermidis was perceived as non-pathogenic. The growing trend in modern healthcare towards interventional and invasive techniques has contributed to the rise of S. epidermidis as a notable pathogen primarily acquired within healthcare settings, particularly concerning prosthetic devices [3]. The capacity of this organism to develop biofilms on foreign objects plays a crucial role in the progression of disease. Within these biofilms, bacteria are encased in a protective extracellular polymeric matrix, providing resistance against both antibiotics and the host immune system [4]. Although recognized as a significant nosocomial pathogen for over 30 years, knowledge about the epidemiology, transmission and molecular biology of S. epidermidis is limited compared to S. aureus [5]. Scientific review of S. epidermidis inevitably involves discussion of S. aureus. Historically, descriptions of S. epidermidis have been shaped by comparisons to S. aureus [6]. Furthermore, the genetically intractable nature of S. epidermidis and the absence of molecular methods specific for the manipulation of the species have hindered its study. In the absence of specific knowledge, there has been a tendency to assume that findings about S. aureus can be extrapolated. However, as multidrug resistance proves increasingly common and the clinical impact and associated economic burden posed by S. epidermidis continue to increase [7], the time for the dedicated study of this organism is long overdue [8].

2. Basic Microbiology

S. epidermidis is a non-motile, non-spore-forming, gram-positive coccus, 0.8 – 1.0 μm in diameter, arranged in pairs and tetrads with occasional single cells (figure 1) [9]. Colonies are circular, 2.5 – 4.0 mm in diameter, smooth, raised, glistening and translucent to slightly opaque; typically, grey or greyish-white in color, rare colonies possess a slightly yellow or brownish pigment [10]; sticky consistency increases with age [11]. The cell wall is composed of peptidoglycan, teichoic acid and lipoteichoic acid. Certain strains can also produce polysaccharide intercellular adhesin (PIA) which can coat the cell and stimulate biofilm formation [12]. *S. epidermidis* can grow from 15 – 45°C, with optimal growth at 30 – 37°C [11]. Although a facultative anaerobe, it grows best under aerobic conditions. The G+C content of its DNA is 33.5 + 0.2% [13].




FIGURE 1. - (A) *Staphylococcus epidermidis* cells (Gram stain). (B) *S. epidermidis* cells (SEM). *S. epidermidis* cells are spherical (0.5–1.5 μm in diameter) and gram-positive

The division of staphylococcal species on the basis of coagulase testing was proposed by Fairbrother in 1940 [14]. For a number of decades, medical microbiologists only focused on identifying the coagulase-positive species, *S. aureus*, based on the assumption that all coagulase negative staphylococci (CNS) were non-pathogenic commensals [11]. In 1974, Kloos and Schleifer introduced the biochemical classification scheme for the differentiation of *Staphylococcus* species, on which current bio typing schemes are based [15]. Consequently, *S. epidermidis* became recognised as the major cause of all CNS infections except those of the urinary tract [15,16-17], with *Staphylococcus saprophyticus* was found to account for 80% (12/15) of female urinary tract infections [18]. The original Kloos and Schleifer scheme described 11 different staphylococcal species [19]. Since then, 54 staphylococcal species have been catalogued by the List of Prokaryotic Names with Standing in Nomenclature (LPSN) database [20].

3. Clinical impact of *S. epidermidis*

Consistently recognised as a leading cause of nosocomial infections, *S. epidermidis* possess significant morbidity and mortality to individual patients and economic burden on healthcare systems. This impact is reflected in the summary data on Antimicrobial-resistant pathogens associated with healthcare-associated infections reported by the Centers for Disease Control and National Healthcare Safety Network, in which CoNS predominantly represented by *S. epidermidis*, were the identified as the: most common cause of central line associated bloodstream infections (CLABSI); second-ranked cause of surgical site infections; and third most reported pathogen for hospital-acquired infections [21].




FIGURE 2. - Clinical impact of *S. epidermidis* (31)

4. Epidemiology of *S. epidermidis*

S. epidermidis is characterized by marked genetic diversity, greater than that observed in other staphylococcal species [3]. To date, the majority of epidemiological studies of *S. epidermidis* have utilized pulsed-field gel electrophoresis (PFGE) as the typing method [22]. Despite pronounced genetic diversity within the species, as demonstrated in community-based colonization studies hospital-based investigations suggest the predominance of a few hospital-associated, epidemic clonal lineages [23].

Individually, most nosocomial transmission studies have mostly focused on the presence of clones within specific high-risk sites, such as the ICU [24], neonatal ICU (NICU) cardiac care centers and haemodialysis unit [25]. Typically, these studies have demonstrated the local prevalence of a few dominant clones. One NICU-based study documented the emergence of a particular *S. epidermidis* clone responsible for 31% (20/65) of bloodstream infections occurring within the unit over a year, as well as the longitudinal persistence of the second clone over the 11-year period of the study [26]. While another prospective Italian study reported *S. epidermidis* to account for 30.4% (56/184) of all NICU-acquired infections over three years, with four main clones noted to cause most infections [26]. Compared to sporadic strains these clones were more antibiotic resistant, particularly to the agents treatment within the unit. This observation of disseminated clones possessing more resistant antibiotic profiles is common to several studies, with methicillin-resistant *S. epidermidis* reported to comprise up to 79% [27] to 92% of hospital isolates. The classification of *S. epidermidis* was revised in 2007, with introduction of an improved multi locus sequence type (MLST) scheme [5]. This saw the reclassification of ST27, previously identified as the major disease-associated strain type, present in hospitals in both the US and Europe [28].

Mode of transmission A limited number of studies have attempted to address the mode of transmission of *S. epidermidis* clones within the hospital environment. These investigations have yielded similar results, indicating the replacement of less drug-resistant colonizing strains with locally prevalent, drug-resistant *S. epidermidis* strains during the course of admission [29]. Both healthcare workers [5,30,31] and the hospital environment [31] have been implicated as potential reservoirs for hospital-adapted *S. epidermidis* clones (figure 3). A study conducted in 1982 by Archer et al. on patients undergoing cardiac surgery at the Medical College of Virginia found that only one in 26

patients who were not previously hospitalized were pre-operatively colonized with multidrug- resistant *S. epidermidis* (MDRSE; defined as resistance to methicillin and gentamicin), however, by day ten post-operatively 80% of patients were colonized [5].




FIGURE 3. - Mode of transmission of *S. epidermidis*

The understanding of virulence factors in *S. epidermidis* remains limited due to its high genetic variability, which may serve as a potential marker and therapeutic target against its invasiveness. Among the various virulence factors identified, our focus in this review primarily revolves around the significant role played by biofilm formation. Furthermore, the ability of *S. epidermidis* to invade human immune defenses and exist as a commensal on the human skin, while still not fully comprehended, renders it as an occasional "accidental pathogen" [2,5].

In contrast to many toxin-producing bacteria, *S. epidermidis* exhibits unique amphipathic peptides called phenol-soluble modulins (PSMs) that serve multiple functions. PSMs interact with biofilm formation, are regulated through quorum sensing, and influence the human innate immune system response, thereby contributing to the development of sepsis. Another noteworthy virulence factor is the glycoprotein hemagglutinin, which induces coagulation of red blood cells (RBCs). *S. epidermidis* hemagglutinin displays resistance to pH variations, temperature changes, protease concentrations, serum proteins, cleanser detergents, and sub-inhibitory antibiotics. These factors play a pivotal role in the pathogenesis of *S. epidermidis* by directly aiding adherence to polymers, which is the initial step in the formation of biofilms and the occurrence of biomaterial-associated infections [32].

FUNDING

No funding received for this work

ACKNOWLEDGEMENT

The authors would like to thank the anonymous reviewers for their efforts.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

- [1] Kloos WE, Musselwhite MS. Distribution and persistence of Staphylococcus and Micrococcus species and other aerobic bacteria on human skin. *Appl Microbiol* 1975;30(3):381–95.
- [2] Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 2012;486(7402):207–14.
- [3] Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev* 2014;27(4):870–926.
- [4] Götz F. Staphylococcus and biofilms. *Mol Microbiol* 2002;43(6):1367–78.
- [5] Archer GL. Molecular epidemiology of multiresistant Staphylococcus epidermidis. *J Antimicrob Chemother* 1988;21(Suppl C):133–8.
- [6] Widerström M. Significance of Staphylococcus epidermidis in health care-associated infections, from contaminant to clinically relevant pathogen: This is a wake-up call! *J Clin Microbiol* 2016;54(7):1679–81.
- [7] Rosenbach A. Mikro-organismen bei den wund-infektionen-krankheiten des menschen. *JF Bergmann*; 1884.
- [8] Welch WH. Conditions underlying the infection of wounds. *Am J Med Sci* 1891;102(5):439–65.
- [9] Hugh R, Ellis MA. The neotype strain for Staphylococcus epidermidis (Winslow and Winslow 1908) Evans 1916. *Int J Syst Bacteriol* 1968;18(3):231–9.
- [10] Otto M. Staphylococcus epidermidis - the “accidental” pathogen. *Nat Rev Microbiol* 2009;7(8):555–67.
- [11] Brinkman CL, Tyner HL, Schmidt-Malan SM, Mandrekar JN, Patel R. Causes and implications of the disappearance of rifampin resistance in a rat model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. *Antimicrob Agents Chemother* 2015;59(8):4481–8.
- [12] Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. *J Bone Joint Surg Am* 2014;96(8):624–30.
- [13] Warren DK, Quadir WW, Hollenbeak CS. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. *Cri Care Med* 2006;34(8):2084–2089.
- [14] De Vos P, Garrity G, Jones D, Krieg NR, Ludwig W. “The firmicutes”. *Bergeys Manual of systematic bacteriology*, Vol 3. New York, USA. In: Family VIII. Staphylococcaceae. 2009. Pages 392–421.
- [15] Schleifer KH, Kloos WE. Isolation and characterization of staphylococci from human skin. *Int J Syst Bacteriol* 1975;25(1):50–61.
- [16] Winslow AR, Winslow CEA. The systematic relationships of the Coccaceae, with a discussion of the principles of bacterial classification. 1st ed. New York: Wiley; 1908.
- [17] Jones D, Deibel RH, Niven CF. Identity of Staphylococcus epidermidis. *J Bacteriol* 1963;85(1):62–7.
- [18] Fairbrother RW. Coagulase production as a criterion for the classification of the staphylococci. *J Pathol Bacteriol* 1940;50(1):83–8.
- [19] Kloos WE, Schleifer KH. Simplified scheme for routine identification of human Staphylococcus species. *J Clin Microbiol* 1975;1(1):82–8.
- [20] Masik FJ, Brake S. Species identification and susceptibility to 17 antibiotics of coagulase-negative staphylococci isolated from clinical specimens. *J Clin Microbiol* 1982;15(4):640–5.
- [21] Christensen GD, Parisi JT, Bisno AL, Simpson WA, Beachey EH. Characterization of clinically significant strains of coagulase-negative staphylococci. *J Clinical Microbiol* 1983;18(2):258–69.
- [22] Freeman R, Hjørsing N. Species of coagulase-negative staphylococci isolated from catheter tips from open-heart surgery patients. *Thorax* 1980;35(5):359–62.
- [23] Parte AC. LPSN - list of prokaryotic names with standing in nomenclature. *Nucleic Acids Res* 2014;42(Database issue):D613–6.
- [24] Parte AC. LPSN - List of prokaryotic names with standing in nomenclature (bacterio.net), 20 years on. *Int J Syst Evol Microbiol* 2018;68(6):1825–9.
- [25] Euzéby JP. List of bacterial names with standing in nomenclature: a folder available on the internet. *Int J Syst Bacteriol* 1997;47(2):590–2.
- [26] Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. *Infect Control Hosp Epidemiol* 2013;34(1):1–14.
- [27] Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. *Arch Surg* 2001;136(2):229–34.

- [28] Sgro M, Shah PS, Campbell D, Tenuta A, Shivananda S, Lee SK, et al. Early-onset neonatal sepsis: rate and organism pattern between 2003 and 2008. *J Perinatol* 2011;31(12):794–8.
- [29] Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. *Lancet* 2017;390(10104):1770–80.
- [30] Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. *Pediatrics* 2002;110(2 Pt 1):285–91.
- [31] Karchmer AW, Archer GL, Dismukes WE. *Staphylococcus epidermidis* causing prosthetic valve endocarditis - Microbiologic and clinical observations as guides to therapy. *Ann Intern Med* 1983;98(4):447–55.
- [32] Lalani T, Kanafani ZA, Chu VH, Moore L, Corey GR, Pappas P, et al. Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International Collaboration on Endocarditis Merged Database. *Eur J Clin Microbiol Infect Dis* 2006;25(6):365–8.